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Opinion  
Hypertension is a leading risk factor for morbi-mortality 
and disability. It is estimated that approximately 875 million 
adults worldwide have systolic blood pressure above 140mmHg. 
If the demographic trend is considered and the prevalence of 
hypertension increases with age, the consequences of hypertension 
will continue to increase. The 2017 guideline is an update of “The 
Seven Report of the Joint Committee on Prevention, Detection, 
Evaluation and Treatment of High Blood Pressure (JNC)” [1,2].
The guidelines provide a comprehensive review for the 
diagnosis and therapeutics of arterial hypertension. These 
guides recommend classifying blood pressure into 4 categories: 
normal (less than 120/80mm Hg); elevated (120-129/lower 
80mmHg); stage 1 hypertension (130-139/80mmHg) and 
stage 2 hypertension (greater 140/greater 90mmHg). These 
categories are designed to facilitate clinical decisions and reflect 
observational cardiovascular risk data with a gradient of growth as 
blood pressure increases. You must think that not all populations 
have the same risk, the cardiovascular risk is not the same in the 
Mediterranean or in South America than in the USA [1].
An important change is the strong recommendation for taking 
blood pressure out of the consultation to perform diagnosis 
and monitoring of blood pressure. Self-measurement (AMPA) 
and ambulatory monitoring (ABPM) of blood pressure should 
be encouraged. Evidence IA. This recommendation reflects the 
frequent inconsistencies between office and home BP values 
(masked and white-coat hypertension) intensely discussed in 
these guidelines. In this way, recently, Quer et al. [3] showed 
fascinating data analysis of home blood pressure metrics. It 
showed that the BP values significantly decrease after 10 minutes 
from the initial measurement (4.1 and 6.6 mmHg for the diastolic 
and systolic BP, respectively), and continue to decrease for about 
25 minutes [1,3].
Non-pharmacological therapies have high evidence (IA) in 
the new guidelines for the treatment of hypertension. We must 
continue to insist with them always. These interventions include 
weight loss in overweight or obese patients; healthy diet, such 
as the DASH diet (Dietary Approaches to Stop Hypertension); 
sodium reduction; the supplement with potassium; the increase 
of physical activity; and moderation in the consumption of 
alcoholic beverages. These measures can reduce blood pressure 
5 to 10mmHg [1].
The next point, I find controversial, and that is when we should 
start pharmacological therapy? and at this point the guidelines is 
consistent with the changes proposed. Pharmacological therapy is 
recommended to start it in patients with high cardiovascular risk 
and blood pressure values of 130/80mm Hg or more. Also in those 
patients without cardiovascular risk or with low risk and blood 
pressure values above 140/90mmHg. The latter does not present 
changes with respect to the recommendation of the JNC 8, but 
although the evidence has a strong recommendation, its origin is 
more indirect, since the data arise from a meta-analysis that does 
not show significant differences in [1].
To stratify the risk, the guide proposes to use the ASCVD risk 
score that estimates the risk of myocardial infarction, stroke or 
death from ischemic heart disease at 10 years [1]. The most recent 
studies, both randomized and observational trials, reconcile the 
idea that the lower blood pressure thresholds are beneficial 
in patients with high cardiovascular risk and those older than 
75 years. Undoubtedly, the balance of the potential benefits 
of controlling the presence of hypertension and the costs of 
medication, adverse effects and poly-pharmacy for each individual 
patient should be considered. There is little high quality evidence 
in the literature about some patient populations, especially the 
frail elderly [4].
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I think we can point out that, in these guidelines, the role 
of self-monitoring has been highlighted, as evidenced by the 
evidence, and this is very useful for patients to assume a more 
responsible and active behavior about their disease. However, 
this new paradigm in the diagnosis of blood pressure, at least for 
the rest of the world, is still scarce in strong evidence and much 
anticipated and I do not think it can be reflected in the short term 
in other consensus or guidelines. 
But there are data that stand out in addition to the objectives, 
such as self-monitoring, the use of fixed doses in severe 
hypertensive patients, the initiation of early treatment in high-
risk cardiovascular patients and in special populations, which are 
very useful for the management of patients in the doctor’s office.
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